MX356728B - Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. - Google Patents
Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.Info
- Publication number
- MX356728B MX356728B MX2013013198A MX2013013198A MX356728B MX 356728 B MX356728 B MX 356728B MX 2013013198 A MX2013013198 A MX 2013013198A MX 2013013198 A MX2013013198 A MX 2013013198A MX 356728 B MX356728 B MX 356728B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pharmaceutical combination
- diabetes type
- diabetes
- type
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente invención se refiere a una combinación farmacéutica para su uso en el tratamiento de un paciente que padece diabetes de tipo2, comprendiendo dicha combinación (a) desPro36Exendin-4(1-39)-LuS6-NH2 y/o una sal farmacéuticamente aceptable de la misma, y (b) metformina y/o una sal farmacéuticamente aceptable de la misma en la que el compuesto (a) se administra una vez al día en un intervalo de 4h a 15 min antes del desayuno (morning meal), en donde el paciente que ha de tratarse posee una concentración de glucosa plasmática postprandial de 2 horas de al menos 14 mmol/L, y en donde el paciente que ha de tratarse posee una fluctuación del nivel de glucosa de al menos 5 mmol/L, en donde la fluctuación del nivel del glucosa es la diferencia entre la concentración de glucosa plasmática postprandial de 2 horas y la concentración de glucosa plasmática 30 minutos antes de una comida de ensayo y en donde la diabetes de tipo 2 que ha de tratarse no está controlada adecuadamente mediante tratamiento con sólo metformina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166052 | 2011-05-13 | ||
| PCT/EP2012/058779 WO2012156312A1 (en) | 2011-05-13 | 2012-05-11 | Pharmaceutical combination for use in the treatment of diabetes type 2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013198A MX2013013198A (es) | 2014-02-20 |
| MX356728B true MX356728B (es) | 2018-06-12 |
Family
ID=46052773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013198A MX356728B (es) | 2011-05-13 | 2012-05-11 | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130040878A1 (es) |
| EP (1) | EP2709652A1 (es) |
| JP (1) | JP6005140B2 (es) |
| KR (1) | KR20140041553A (es) |
| CN (2) | CN103648519A (es) |
| AR (1) | AR086356A1 (es) |
| AU (1) | AU2012257780B2 (es) |
| BR (1) | BR112013029256A8 (es) |
| CA (1) | CA2835336A1 (es) |
| MX (1) | MX356728B (es) |
| RU (2) | RU2017129878A (es) |
| WO (1) | WO2012156312A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122013025625B1 (pt) | 2008-10-17 | 2021-08-03 | Sanofi-Aventis Deutschland Gmbh | Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo |
| DK2498802T3 (en) | 2009-11-13 | 2015-04-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| MY159565A (en) | 2009-11-13 | 2017-01-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| KR101983982B1 (ko) | 2011-08-29 | 2019-05-30 | 사노피-아벤티스 도이칠란트 게엠베하 | 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| SG10201704716XA (en) * | 2013-01-17 | 2017-07-28 | Vtv Therapeutics Llc | Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| CN105960249B (zh) | 2014-01-09 | 2021-03-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 |
| WO2015104310A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| BR112016013832A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| DK2324853T3 (en) * | 2009-11-13 | 2015-11-30 | Sanofi Aventis Deutschland | Lixisenatide as an add-on to metformin to treat diabetes type 2 |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法 |
-
2012
- 2012-05-10 US US13/468,422 patent/US20130040878A1/en not_active Abandoned
- 2012-05-11 EP EP12720196.0A patent/EP2709652A1/en not_active Withdrawn
- 2012-05-11 CA CA2835336A patent/CA2835336A1/en not_active Abandoned
- 2012-05-11 RU RU2017129878A patent/RU2017129878A/ru not_active Application Discontinuation
- 2012-05-11 WO PCT/EP2012/058779 patent/WO2012156312A1/en active Application Filing
- 2012-05-11 AR ARP120101668A patent/AR086356A1/es unknown
- 2012-05-11 MX MX2013013198A patent/MX356728B/es active IP Right Grant
- 2012-05-11 RU RU2013155480/15A patent/RU2013155480A/ru unknown
- 2012-05-11 CN CN201280034724.7A patent/CN103648519A/zh active Pending
- 2012-05-11 JP JP2014509759A patent/JP6005140B2/ja not_active Expired - Fee Related
- 2012-05-11 AU AU2012257780A patent/AU2012257780B2/en not_active Ceased
- 2012-05-11 BR BR112013029256A patent/BR112013029256A8/pt not_active Application Discontinuation
- 2012-05-11 KR KR1020137033311A patent/KR20140041553A/ko active Search and Examination
- 2012-05-11 CN CN201810748089.8A patent/CN109045283A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20130040878A1 (en) | 2013-02-14 |
| MX2013013198A (es) | 2014-02-20 |
| JP2014518860A (ja) | 2014-08-07 |
| BR112013029256A2 (pt) | 2016-11-29 |
| WO2012156312A1 (en) | 2012-11-22 |
| AU2012257780B2 (en) | 2017-06-01 |
| KR20140041553A (ko) | 2014-04-04 |
| CA2835336A1 (en) | 2012-11-22 |
| RU2017129878A (ru) | 2019-02-05 |
| JP6005140B2 (ja) | 2016-10-12 |
| AR086356A1 (es) | 2013-12-04 |
| EP2709652A1 (en) | 2014-03-26 |
| BR112013029256A8 (pt) | 2018-01-16 |
| CN109045283A (zh) | 2018-12-21 |
| CN103648519A (zh) | 2014-03-19 |
| RU2013155480A (ru) | 2015-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX2014002159A (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| PL2683395T3 (pl) | Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1 | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| MX366090B (es) | Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| AP2014007533A0 (en) | Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases | |
| GB201118656D0 (en) | New compounds | |
| MX2019003249A (es) | Diagnostico, prevencion y tratamiento de enfermedades de la articulacion. | |
| AP2014007399A0 (en) | Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament | |
| UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
| HK1194302A1 (zh) | 紫檀茋在製造用於治療、緩解或預防焦慮的藥物組合物中的應用 | |
| MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| IN2015DN00515A (es) | ||
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| UA115307C2 (uk) | Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри | |
| IN2014KN01772A (es) | ||
| HUP1200552A2 (en) | Pharmaceutical compositions for the treatment of high blood pressure | |
| UA97054C2 (ru) | Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ | |
| MX2019008148A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| MX2015008454A (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
| HK1196953A1 (zh) | 用於治療糖尿病的製劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |